Orchard Therapeutics

$4.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.96%) As of 11:41 AM EST today

Why Robinhood?

You can buy or sell ORTX and other stocks, options, and ETFs commission-free!

About ORTX

Orchard Therapeutics plc American Depositary Shares, also called Orchard Therapeutics, is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. The listed name for ORTX is Orchard Therapeutics plc American Depositary Shares.

CEO
Bobby Gaspar
Employees
252
Headquarters
London, Greater London
Founded
2018
Market Cap
450.32M
Price-Earnings Ratio
Dividend Yield
Average Volume
749.34K
High Today
$4.73
Low Today
$4.58
Open Price
$4.68
Volume
87.87K
52 Week High
$15.93
52 Week Low
$3.76

Collections

ORTX Earnings

-$0.56
-$0.37
-$0.19
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like